Bavarian Nordic reports preliminary CV-301 data

Bavarian Nordic A/S (CSE:BAVA) said CV-301 plus docetaxel led to progression-free survival of 6.6 months vs. 3.8 months for docetaxel alone in a Phase II trial to treat metastatic breast cancer (p=0.12). According to the company, the trial was not designed to reach statistical significance due to its size and therefore the company considers the p-value to be a "successful outcome." The open-label, U.S. trial enrolled 48 patients. Data were presented at the European Society for Medical Oncology meeting in Vienna. Final data are expected this quarter, at which point the company said it will determine its future development strategy for CV-301. ...